Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
CE Teunissen, IMW Verberk, EH Thijssen… - The Lancet …, 2022 - thelancet.com
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …
recent results have shown that they could become a reality. Convincing data generated with …
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …
that is closely linked both spatially and temporally to emergence of neurodegeneration and …
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring
Blood biomarkers indicative of Alzheimer's disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for …
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for …
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
CR Jack Jr, JS Andrews, TG Beach… - Alzheimer's & …, 2024 - Wiley Online Library
Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …
separate work groups in 2011 and single work groups in 2012 and 2018 to create …
Performance of plasma phosphorylated tau 181 and 217 in the community
Plasma phosphorylated tau 181 (P-tau181) and 217 (P-tau217) are indicators of both
amyloid and tau pathology in clinical settings, but their performance in heterogeneous …
amyloid and tau pathology in clinical settings, but their performance in heterogeneous …
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic …
Background Plasma tau phosphorylated at threonine 217 (p-tau217) and plasma tau
phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau …
phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau …
Blood biomarkers for Alzheimer's disease in clinical practice and trials
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape
Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change
Plasma biomarkers related to amyloid, tau, and neurodegeneration (ATN) show great
promise for identifying these pathological features of Alzheimer's Disease (AD) as shown by …
promise for identifying these pathological features of Alzheimer's Disease (AD) as shown by …